Vaccine R&D infrastructure
4 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- EATRIS ERIC
European infrastructure consortium accelerating translational medicine through shared facilities, FAIR data services, and biomarker validation across 30+ countries.
“Participated in TRANSVAC2 and TRANSVAC-DS, supporting European vaccine development infrastructure and design studies.”
NL20 projects - INSTRUCT ACADEMIC SERVICES LIMITED
Pan-European research infrastructure providing integrated access to structural biology techniques (NMR, EM, X-ray crystallography) for life sciences and drug discovery.
“TRANSVAC2 participation (2017-2023) connects structural biology capabilities to vaccine research and development infrastructure.”
UK7 projects - STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Dutch primate research center specializing in preclinical vaccine evaluation for infectious diseases, with deep ties to European vaccine infrastructure programs.
“TRANSVAC2 (EUR 2.6M, their largest grant) and TRANSVAC-DS both build European vaccine research and development infrastructure.”
PrimaryNL7 projects - INTRAVACC BV
Dutch vaccine development and manufacturing specialist contributing to European vaccine R&D infrastructure and quality control standards.
“TRANSVAC2 and TRANSVAC-DS both aimed at building and designing European vaccine research and development infrastructure.”
NL3 projects